EAN News
EMA communication: No change is needed in use of direct oral anticoagulants following EMA-funded study
No change to the conditions of use of the direct oral anticoagulants
Eliquis (apixaban), Pradaxa (dabigatran etexilate) and Xarelto (rivaroxaban) is
needed following a review of the results of a European study of real-world data
for these medicines.
The study,… Continue Reading









